NFKB1 and colitis: Concurrently with our results, Koyuncu et al. (2024) demonstrated that it inhibited inflammation; additionally, they found that 0.4 and 0.8 mL/kg PSO decreased NF-κB activation in liver and kidney tissues inside a colitis model [14].